Boston Biomedical Innovation Center (B-BIC) is a life sciences accelerator funded by the National Institutes of Health and our member institutions to increase the return on investment in research. We speed the translation of research technologies into products for doctors and their patients, for the good of society.
Our members are a consortium of academic medical centers in Boston including Brigham and Women’s Hospital, Harvard Medical School, Massachusetts General Hospital, and the Massachusetts Institute of Technology.
B-BIC provides funding for technology development and translational research, including regulatory, reimbursement, and business development aspects that are part of an overall commercialization strategy.
Contributed by Ed Berger Principal Larchmont Strategic Advisors Reimbursement strategy counsel to companies across the life sciences spectrum A basic understanding of the healthcare reimbursement system is an important success factor for any entrepreneur developing a new medical product. Reimbursement is critical to opportunity assessment, business plan development, investor due diligence, and commercial success. The…Read More
Keep pitch short and focused on the technology and its commercial application. Limit the discussion of preliminary results, and focus on the most relevant results with conclusions – not data. Present the science within the context of the business strategy. FAST PITCH FOR FUNDING is Friday, October 12, 2018 from 10am – 12pm at TUFTS UNIVERSITY, 145 Harrison Ave, Room…Read More
Q: Do I need to have slides? A: Pitches only need to address the suggested elements. Use of reference materials or other visual elements is welcome if they help convey the product concept and can be shared using your laptop screen. AV equipment will not be available. Q: How formal will the pitches be? A:…Read More
Contributed by Lesley Watts, Director of B-BIC Operations & Finance Intellectual property is the product of a person’s creativity and it can take several forms including patents, copyright, trademarks, and trade secrets. Patents play a key role in innovation and economic development, particularly in the life sciences, because they allow the patent holder to capture the…Read More
WATCH: B-BIC’s Work With Platelet Biogenesis One of B-BIC’s first grant recipients was Jonathan Thon, a researcher based at Brigham and Women’s Hospital. Jonathan and his team had been researching two technologies necessary for producing platelets outside of the body. They had achieved promising results that demonstrated a microfluidic platform could simulate bone marrow physiological…Read More
Contributed by John Randle, Phd B-BIC COACH PRINCIPAL, RANDOM WALK VENTURES, LLC COO, KANTUM BIO Most new technologies and products will require regulatory scrutiny and approval prior to marketing. These requirements vary widely depending on the nature of the technology/product and their intended medical use, as well as the regulatory precedent set by existing…Read More
RECIPIENT: Dr. Ehud Schmidt TITLE: An MRI-Compatible Voltage Device Tracking For Multimodality Electrophysiology TYPE OF AWARD: PILOT INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Ehud Schmidt, PhD, Director of Engineering Physics in the Department of Radiology, Brigham and Women’s Hospital, and Associate Professor at Harvard Medical School receives a Pilot award to develop MRI-compatible voltage device tracking for multimodality…Read More
RECIPIENT: Dr. Warren Zapol TITLE: Portable and Affordable Lightweight NO Generator TYPE OF AWARD: DRIVE INSTITUTION: MGH DESCRIPTION: Warren Zapol, MD, Director of the MGH Anesthesia Center for Critical Care Research at Massachusetts General Hospital, receives a DRIVE award to develop electric nitric oxide generation for medical purposes. Inhaled nitric oxide (NO) was approved by the FDA…Read More
Contributed by Erin McKenna, B-BIC Deputy Director After the dip in investment in early-stage biotechnology in 2008, the number of funding opportunities for early-stage technologies has been increasing in recent years. Despite this promising trend, finding and securing the funding necessary to move your research out of the lab and towards commercialization is still a…Read More
Contributed by Josh Tolkoff The most common reason for the commercial failure of a start-up entity is not having a compelling clinical need. What exactly is an “unmet need”? An unmet need is something more than an incremental improvement, and once it exists in the market it will make a substantial change for the better.…Read More
Contributed by Ron Blackman In our previous newsletter, we described how to identify the unmet need that will be served by your device or therapeutic, and here we will help you build the case that you have a solution to meet that need. A number of points should be addressed and we will go through…Read More
Contributed by John Randle, Phd B-BIC COACH PRINCIPAL, RANDOM WALK VENTURES, LLC COO, KANTUM BIO The first step in defining your competitive landscape is to identify and define the technology’s current competition and how they fit into or define current standard of care (SoC). List the products or substitutes that you would aim to replace…Read More
Contributed by John Randle, Phd B-BIC COACH PRINCIPAL, RANDOM WALK VENTURES, LLC COO, KANTUM BIO As you prepare to move your technology or product out of the academic setting towards commercial development, a key step is to define the market potential for your technology/product. Prospective investors will assess the opportunity in terms of the potential…Read More
RECIPIENT: Dr. Jonghan Kim TITLE: Hydrogel-based nanochelator therapy for iron overload disorders TYPE OF AWARD: Drive TECHNOLOGY TYPE: Small Molecule CLINICAL AREA: Blood INSTITUTION: Northeastern & MGH DESCRIPTION: Iron overload, best represented by hereditary hemochromatosis (primary/genetic iron overload) and transfusional hemoglobinopathy (secondary/acquired iron overload), is a well-defined risk factor for several critical diseases, including heart failure, liver cirrhosis, arthritis,…Read More
RECIPIENT: Dr. J. Brian McAlvin TITLE: A Novel Method To Treat The Systemic Inflammatory Response Syndrome (SIRS) TYPE OF AWARD: Pilot TECHNOLOGY TYPE: Therapeutic Device CLINICAL AREA: Blood INSTITUTION: Boston Children’s Hospital DESCRIPTION: We have developed highly-selective blood-filtering devices that are capable of filtering of individual, harmful molecules from the blood of patients rendered critically ill by the…Read More